At the end of April 2023, Solopharm successfully launched two new production areas at the liquid dosage forms and dietary supplements factories.
The total investment in both projects counted more than 2 bn rubles. Within the year on the sites which cover 1,100 m2 and 1,250 m2 each, six modern, high-performance, and automated lines were launched.
The increase in production capacity and the launch of new lines contribute to the achievement of three key goals simultaneously:
1. Opens the potential for the new drugs development and production in various therapeutic areas.
2. Allows to fulfill the lack of highly demanded drugs on the pharmacy’s shelves in such areas as: otorhinolaryngology, ophthalmology, therapy, pulmonology, neurology, and injection solutions.
3. Creates new workplaces.
For reference:
Solopharm (Grotex LLC) is a leading pharmaceutical manufacturer of liquid and solid dosage forms, which has been awarded the status of a strategically important pharmaceutical enterprise in Russia.
The company started operating in 2014 and has already 5 production sites with a total area of more than 38,000 m2. Own R&D department, analytical and microbiological laboratories allow Solopharm to provide a full cycle of the pharmaceutical development.
Today, the company has almost 1,800 employees, and the drug portfolio includes more than 210 market authorizations.
